Aclidinium bromide vs Umeclidinium
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Obstructive Pulmonary Disease
Shared mechanism: Muscarinic acetylcholine receptor (M3) · full Chronic Obstructive Pulmonary Disease pipeline
Aclidinium bromide · Tudorza Pressair
Marketed by Azurity Pharmaceuticals and partners
NCT00363896 · Phase 3 · completed
The trial randomized 843 participants to double-blind aclidinium or placebo, with trough FEV1 at 12 and 28 weeks, an accepted lung-function endpoint for COPD, as its primary outcome. The registry posts no significance test, but the publication of ACCLAIM/COPD I reports trough FEV1 improvements over placebo of 61 mL and 67 mL at 12 and 28 weeks (both p<0.001).
Reported efficacy
Change From Baseline in Morning Pre-dose (Trough) FEV1 for Aclidinium Bromide (Week 24, morning pre-dose (trough)): Change from baseline in morning pre-dose (trough) FEV1 at Week 24, aclidinium bromide 400 μg vs placebo: LS mean difference 0.134 L (p<0.001); AB 400 μg 0.050 L vs placebo -0.084 L. (met)
Result source: NCT03022097
Umeclidinium · Incruse Ellipta
Marketed by GlaxoSmithKline
NCT02184611 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial in 308 patients using lung function (trough FEV1) as its primary measure, and umeclidinium produced a significantly greater improvement than placebo (least-squares mean difference 0.154 L, 95% CI 0.113 to 0.194, p<0.001).
Reported efficacy
Change From Baseline in Trough (Pre-bronchodilator) Forced Expiratory Volume in 1 Second (FEV1) on Treatment Day 169 (Baseline (Day 1) and Day 169): Change from baseline in trough FEV1 at Day 169 (primary endpoint): UMEC 62.5 mcg vs placebo, LS mean treatment difference 154 mL (95% CI 113, 194; p<0.001) (met)
Result source: NCT02184611
Results for Chronic Obstructive Pulmonary Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Aclidinium bromide | Umeclidinium |
|---|---|---|
| Moderate or severe exacerbations, annualised rate | 0.4 vs 0.6−0.1 vs placeboNCT01966107 | —Trial running · NCT06474039 |
| Trough FEV1, change | 0.1 vs -0.1+0.2 vs placeboNCT0302209725 other results
| 0.1 vs -0.0+0.2 vs placeboNCT0218461121 other results
|
| SGRQ total, change | -8.7 vs -4.7−4 vs placeboNCT030220977 other results
| -6.2 vs -2.1−4 vs placeboNCT021526055 other results
|
| TDI focal score | 2.9 vs 2.1+0.8 vs placeboNCT030220975 other results
| 2.5 vs 1.6+0.9 vs placeboNCT02184611 |
Moderate or severe exacerbations, annualised rate
- Aclidinium bromide
- 0.4 vs 0.6−0.1 vs placeboNCT01966107
- Umeclidinium
- —Trial running · NCT06474039
Trough FEV1, change
- Aclidinium bromide
- 0.1 vs -0.1+0.2 vs placeboNCT03022097
25 other results
- 0.1 vs -0.1 NCT03022097
- 0.1 vs -0.1 NCT03022097
- 0.1 vs -0.1 NCT03022097
- 0.1 vs -0.1 NCT01001494
- 0.1 vs -0.0 NCT01437397
- 0.1 vs -0.0 NCT01437397
- 0.1 vs -0.1 NCT01462942
- 0.1 vs -0.1 NCT01462942
- 1.2 vs 1.2 NCT00358436
- 1.2 vs 1.2 NCT00358436
- 0.1 vs -0.0 NCT00891462
- 0.1 vs -0.0 NCT01045161
- 0.1 vs -0.0 NCT01001494
- 0.0 vs -0.1 NCT01001494
- 0.1 vs -0.0 NCT00891462
- 0.0 vs -0.0 NCT01045161
- 0.0 vs -0.0 NCT01001494
- 0.1 vs 0.1 NCT02796677
- 0.0 vs -0.1 NCT01572792
- 0.0 vs -0.1 NCT01572792
- 0.1 vs -0.0 NCT00500318
- 0.1 vs -0.0 NCT02153489
- 0.1 vs -0.0 NCT01120093
- 0.1 vs -0.0 NCT01120093
- 0.1 vs -0.0 NCT01120093
- Umeclidinium
- 0.1 vs -0.0+0.2 vs placeboNCT02184611
21 other results
- 0.1 vs -0.0 NCT01957163
- 0.1 vs -0.0 NCT01772147
- 0.1 vs -0.0 NCT01957163
- 0.1 vs -0.0 NCT01772134
- 0.1 vs -0.0 NCT01772147
- 0.1 vs -0.0 NCT01772134
- 0.1 vs -0.0 NCT02119286
- 0.1 vs -0.0 NCT02119286
- 0.2 vs 0.1 NCT02207829
- 0.2 vs 0.2 NCT02257385
- 0.1 vs 0.1 NCT02729051
- 0.2 vs 0.0 NCT02152605
- 0.2 vs 0.1 NCT01879410
- 0.1 vs -0.0 NCT02257372
- 0.1 vs -0.0 NCT03034915
- 0.1 vs 0.1 NCT02236611
- 0.1 vs 0.1 NCT02164539
- 0.2 vs 0.1 NCT02164539
- 0.1 vs 0.1 NCT02164539
- 0.2 vs 0.1 NCT02164539
- 0.2 vs -0.0 NCT02275052
SGRQ total, change
- Aclidinium bromide
- -8.7 vs -4.7−4 vs placeboNCT03022097
7 other results
- -7.6 vs -4.7 NCT03022097
- -6.6 vs -2.2 NCT01437397
- -5.9 vs -2.2 NCT01437397
- -7.2 vs -6.5 NCT01462942
- -8.3 vs -6.5 NCT01462942
- -3.6 vs -1.9 NCT01572792
- -5.5 vs -1.9 NCT01572792
- Umeclidinium
- -6.2 vs -2.1−4 vs placeboNCT02152605
5 other results
- -7.3 vs -4.3 NCT02184611
- -7.0 vs -2.5 NCT02184611
- -5.8 vs -1.4 NCT02184611
- -5.8 vs -4.9 NCT02729051
- -5.0 vs -3.3 NCT03034915
TDI focal score
- Aclidinium bromide
- 2.9 vs 2.1+0.8 vs placeboNCT03022097
5 other results
- 2.6 vs 2.1 NCT03022097
- 2.0 vs 0.6 NCT01437397
- 2.0 vs 0.6 NCT01437397
- 2.5 vs 1.2 NCT01462942
- 2.4 vs 1.2 NCT01462942
- Umeclidinium
- 2.5 vs 1.6+0.9 vs placeboNCT02184611
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
5 other shared endpoints and safety
Coverage. Aclidinium bromide: 9 of 9 rows · Umeclidinium: 9 of 9 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Aclidinium bromide Rows use multiple source trials | Umeclidinium Rows use multiple source trials |
|---|---|---|
| E-RS Total absolute change · score | -1.75 vs -0.73 placebo score @ 8wk400 μga,b,c NCT02375724 · Phase 4 · registry result, not featured evidence | -1.52 vs -0.99 UMEC score @ 24wk62.5/25 mcga,b,c NCT03034915 · Phase 4 · registry result, not featured evidence |
| Exercise Endurance Time Seconds absolute value · seconds | 68.3 vs 9.8 placebo seconds @ 3wk400 μg BIDd,a,b,e NCT01471171 · Phase 3 · registry result, not featured evidence | -2.06 vs -5.37 placebo seconds @ 12wk62.5/25 mcgd,a,b,e NCT02275052 · Phase 4 · registry result, not featured evidence |
| FRC Change absolute change · L | -0.138 vs -0.076 placebo L @ 6wkd,a,b,f NCT00500318 · Phase 3 · registry result, not featured evidence | -0.457 vs -0.111 placebo L @ 12wk62.5/25 mcgd,a,b,f NCT02275052 · Phase 4 · registry result, not featured evidence |
| TDI Focal absolute value · score | 1.812 vs 0.731 placebo score @ 52wk400/12 μgg,d,a,b,h NCT01572792 · Phase 3 · registry result, not featured evidence show 1 more dose1.742 vs 0.731 placebo score @ 52wk400/6 μg NCT01572792 · Phase 3 · registry result, not featured evidence | 1.68 vs 1.3 UMEC score @ 24wk62.5/25 mcgd,a,b,h NCT03034915 · Phase 4 · registry result, not featured evidence |
| Time to First Moderate or Severe Exacerbation time to event · months | NA vs NA placebo months @ 52wk200 μg once-dailya,b,i NCT00358436 · Phase 3 · monotherapy | NA vs NA FF/VI + UMEC months100/62.5/25a,b,i NCT02729051 · Phase 3 · registry result, not featured evidence |
| Dropout rate | 14.2%200 μg Once-dailyj NCT00363896 · Phase 3 · monotherapy show 34 more results25.7%200 μg once-daily NCT00358436 · Phase 3 · monotherapy 7.1%400 μg NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 7.9%400/12 μg NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 —400 μg Bid NCT01120093 · Phase 2 —200 μg Bid NCT01120093 · Phase 2 —100 μg Bid NCT01120093 · Phase 2 12.6%400µg NCT00891462 · Phase 3 17.8%200µg NCT00891462 · Phase 3 —400 μg NCT01045161 · Phase 3 —400 μg NCT01045161 · Phase 3 —200 μg NCT01045161 · Phase 3 —200 μg to 400 μg NCT01045161 · Phase 3 6.3%400 μg Bid NCT01001494 · Phase 3 8.7%200 μg Bid NCT01001494 · Phase 3 44.3% NCT01966107 · Phase 4 4.4%400 μg NCT02375724 · Phase 4 · registry result, not featured evidence —400 μg bid NCT02153489 · Phase 4 · registry result, not featured evidence —400/12 μg NCT02796677 · Phase 3 · registry result, not featured evidence 19.5%400/12 μg NCT01572792 · Phase 3 · registry result, not featured evidence 18.3%400/6 μg NCT01572792 · Phase 3 · registry result, not featured evidence 19.5%400/12 μg NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3 18.3%400/6 μg NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3 8.8%400/12 μg NCT01462942 · Phase 3 · registry result, not featured evidence 10.5%400/6 μg NCT01462942 · Phase 3 · registry result, not featured evidence —400 μg BID NCT01471171 · Phase 3 · registry result, not featured evidence 2.9%400 µg BID NCT01462929 · Phase 3 · registry result, not featured evidence 44.7%400µg NCT01044459 · Phase 3 · registry result, not featured evidence 42.6%200µg NCT01044459 · Phase 3 · registry result, not featured evidence —400 μg NCT00970268 · Phase 3 · registry result, not featured evidence —400 μg NCT00970268 · Phase 3 · registry result, not featured evidence —200 μg NCT00970268 · Phase 3 · registry result, not featured evidence —200 μg NCT00970268 · Phase 3 · registry result, not featured evidence 5.8% NCT00500318 · Phase 3 · registry result, not featured evidence —400 μg Bid NCT00868231 · Phase 2 · registry result, not featured evidence | 13.7%62.5 mcgk NCT02184611 · Phase 3 show 25 more results8.9%125 µg QD NCT01772147 · Phase 3 · combination 12.3%62.5 µg QD NCT01772147 · Phase 3 · combination 5.3%62.5 µg NCT01957163 · Phase 3 · combination 8.7%125 µg NCT01957163 · Phase 3 · combination 3.4%125 µg NCT02119286 · Phase 3 · combination 5.3%62.5 µg NCT02119286 · Phase 3 · combination 10.7%125 µg QD NCT01772134 · Phase 3 · combination 6.9%62.5 µg QD NCT01772134 · Phase 3 · combination 11.7%62.5/25 mcg NCT03034915 · Phase 4 · registry result, not featured evidence —62.5/25 mcg NCT02275052 · Phase 4 · registry result, not featured evidence 5%62.5 mcg QD NCT02236611 · Phase 4 · registry result, not featured evidence 8.4%62.5 mcg+ICS/LABA NCT02257372 · Phase 4 · registry result, not featured evidence · combination 5.7%100/62.5/25 NCT02729051 · Phase 3 · registry result, not featured evidence 8.3%62.5 mcg QD NCT02207829 · Phase 3 · registry result, not featured evidence 4.6%62.5/25 µg NCT02257385 · Phase 3 · registry result, not featured evidence 7.3%62.5/25 mcg NCT02152605 · Phase 3 · registry result, not featured evidence —62.5/25mcg NCT02152605 · Phase 3 · registry result, not featured evidence —62.5/25 mcg NCT01879410 · Phase 3 · registry result, not featured evidence —62.5/25 µg NCT02014480 · Phase 3 · registry result, not featured evidence —62.5/25 µg once daily NCT01716520 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3 3.5%100/250 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 4.3%100/125 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 0%100/15.6 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 2.5%100/62.5 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination —100/250/25 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | 3.8%200 μg Once-dailyj NCT00363896 · Phase 3 · monotherapy show 34 more results4.8%200 μg once-daily NCT00358436 · Phase 3 · monotherapy 1.5%400 μg NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 1.1%400/12 μg NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 —400 μg Bid NCT01120093 · Phase 2 —200 μg Bid NCT01120093 · Phase 2 —100 μg Bid NCT01120093 · Phase 2 3.7%400µg NCT00891462 · Phase 3 4.3%200µg NCT00891462 · Phase 3 —400 μg NCT01045161 · Phase 3 —400 μg NCT01045161 · Phase 3 —200 μg NCT01045161 · Phase 3 —200 μg to 400 μg NCT01045161 · Phase 3 1.5%400 μg Bid NCT01001494 · Phase 3 2.9%200 μg Bid NCT01001494 · Phase 3 — NCT01966107 · Phase 4 1.5%400 μg NCT02375724 · Phase 4 · registry result, not featured evidence —400 μg bid NCT02153489 · Phase 4 · registry result, not featured evidence —400/12 μg NCT02796677 · Phase 3 · registry result, not featured evidence 6.2%400/12 μg NCT01572792 · Phase 3 · registry result, not featured evidence 6.5%400/6 μg NCT01572792 · Phase 3 · registry result, not featured evidence 6.2%400/12 μg NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3 6.5%400/6 μg NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3 3.1%400/12 μg NCT01462942 · Phase 3 · registry result, not featured evidence 2.6%400/6 μg NCT01462942 · Phase 3 · registry result, not featured evidence —400 μg BID NCT01471171 · Phase 3 · registry result, not featured evidence 1.8%400 µg BID NCT01462929 · Phase 3 · registry result, not featured evidence 6.8%400µg NCT01044459 · Phase 3 · registry result, not featured evidence 7.1%200µg NCT01044459 · Phase 3 · registry result, not featured evidence —400 μg NCT00970268 · Phase 3 · registry result, not featured evidence —400 μg NCT00970268 · Phase 3 · registry result, not featured evidence —200 μg NCT00970268 · Phase 3 · registry result, not featured evidence —200 μg NCT00970268 · Phase 3 · registry result, not featured evidence 3.5% NCT00500318 · Phase 3 · registry result, not featured evidence —400 μg Bid NCT00868231 · Phase 2 · registry result, not featured evidence | 2.4%62.5 mcgk NCT02184611 · Phase 3 show 25 more results3%125 µg QD NCT01772147 · Phase 3 · combination 4.9%62.5 µg QD NCT01772147 · Phase 3 · combination 1%62.5 µg NCT01957163 · Phase 3 · combination 1.9%125 µg NCT01957163 · Phase 3 · combination 1%125 µg NCT02119286 · Phase 3 · combination 3.4%62.5 µg NCT02119286 · Phase 3 · combination 4.9%125 µg QD NCT01772134 · Phase 3 · combination 2.5%62.5 µg QD NCT01772134 · Phase 3 · combination 3.6%62.5/25 mcg NCT03034915 · Phase 4 · registry result, not featured evidence —62.5/25 mcg NCT02275052 · Phase 4 · registry result, not featured evidence 1.9%62.5 mcg QD NCT02236611 · Phase 4 · registry result, not featured evidence 5.9%62.5 mcg+ICS/LABA NCT02257372 · Phase 4 · registry result, not featured evidence · combination 4%100/62.5/25 NCT02729051 · Phase 3 · registry result, not featured evidence 2%62.5 mcg QD NCT02207829 · Phase 3 · registry result, not featured evidence 2.5%62.5/25 µg NCT02257385 · Phase 3 · registry result, not featured evidence 3.2%62.5/25 mcg NCT02152605 · Phase 3 · registry result, not featured evidence —62.5/25mcg NCT02152605 · Phase 3 · registry result, not featured evidence —62.5/25 mcg NCT01879410 · Phase 3 · registry result, not featured evidence —62.5/25 µg NCT02014480 · Phase 3 · registry result, not featured evidence —62.5/25 µg once daily NCT01716520 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3 —100/250 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination —100/125 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination —100/15.6 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination —100/62.5 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination —100/250/25 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination |
| Serious AEs | 8%200 μg Once-dailyj NCT00363896 · Phase 3 · monotherapy show 34 more results10.3%200 μg once-daily NCT00358436 · Phase 3 · monotherapy 7.9%400 μg NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 7.2%400/12 μg NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 1.4%400 μg Bid NCT01120093 · Phase 2 1.4%200 μg Bid NCT01120093 · Phase 2 0%100 μg Bid NCT01120093 · Phase 2 3.2%400µg NCT00891462 · Phase 3 4.3%200µg NCT00891462 · Phase 3 4.5%400 μg NCT01045161 · Phase 3 9.5%400 μg NCT01045161 · Phase 3 6%200 μg NCT01045161 · Phase 3 13%200 μg to 400 μg NCT01045161 · Phase 3 5.6%400 μg Bid NCT01001494 · Phase 3 4.3%200 μg Bid NCT01001494 · Phase 3 22.8% NCT01966107 · Phase 4 1.5%400 μg NCT02375724 · Phase 4 · registry result, not featured evidence 0%400 μg bid NCT02153489 · Phase 4 · registry result, not featured evidence 7.3%400/12 μg NCT02796677 · Phase 3 · registry result, not featured evidence 7.7%400/12 μg NCT01572792 · Phase 3 · registry result, not featured evidence 6.9%400/6 μg NCT01572792 · Phase 3 · registry result, not featured evidence 5.7%400/12 μg NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3 5.4%400/6 μg NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3 6%400/12 μg NCT01462942 · Phase 3 · registry result, not featured evidence 4.7%400/6 μg NCT01462942 · Phase 3 · registry result, not featured evidence 0%400 μg BID NCT01471171 · Phase 3 · registry result, not featured evidence 1.8%400 µg BID NCT01462929 · Phase 3 · registry result, not featured evidence 10%400µg NCT01044459 · Phase 3 · registry result, not featured evidence 9.3%200µg NCT01044459 · Phase 3 · registry result, not featured evidence 12.3%400 μg NCT00970268 · Phase 3 · registry result, not featured evidence 15.2%400 μg NCT00970268 · Phase 3 · registry result, not featured evidence 14%200 μg NCT00970268 · Phase 3 · registry result, not featured evidence 15.9%200 μg NCT00970268 · Phase 3 · registry result, not featured evidence 2.3% NCT00500318 · Phase 3 · registry result, not featured evidence 0%400 μg Bid NCT00868231 · Phase 2 · registry result, not featured evidence | 8.3%62.5 mcgk NCT02184611 · Phase 3 show 25 more results3%125 µg QD NCT01772147 · Phase 3 · combination 3%62.5 µg QD NCT01772147 · Phase 3 · combination 1%62.5 µg NCT01957163 · Phase 3 · combination 3.4%125 µg NCT01957163 · Phase 3 · combination 1.4%125 µg NCT02119286 · Phase 3 · combination 3.9%62.5 µg NCT02119286 · Phase 3 · combination 2.9%125 µg QD NCT01772134 · Phase 3 · combination 2%62.5 µg QD NCT01772134 · Phase 3 · combination 6%62.5/25 mcg NCT03034915 · Phase 4 · registry result, not featured evidence 3%62.5/25 mcg NCT02275052 · Phase 4 · registry result, not featured evidence 3.3%62.5 mcg QD NCT02236611 · Phase 4 · registry result, not featured evidence 5%62.5 mcg+ICS/LABA NCT02257372 · Phase 4 · registry result, not featured evidence · combination 10.4%100/62.5/25 NCT02729051 · Phase 3 · registry result, not featured evidence 3.3%62.5 mcg QD NCT02207829 · Phase 3 · registry result, not featured evidence 4.4%62.5/25 µg NCT02257385 · Phase 3 · registry result, not featured evidence —62.5/25 mcg NCT02152605 · Phase 3 · registry result, not featured evidence 6.9%62.5/25mcg NCT02152605 · Phase 3 · registry result, not featured evidence 3.2%62.5/25 mcg NCT01879410 · Phase 3 · registry result, not featured evidence 0.5%62.5/25 µg NCT02014480 · Phase 3 · registry result, not featured evidence 1.7%62.5/25 µg once daily NCT01716520 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3 0.5%100/250 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 0%100/125 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 0%100/15.6 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 0%100/62.5 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination 0%100/250/25 µg NCT02164539 · Phase 2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | 200 μg Once-dailyj nasopharyngitis 16.3% (placebo 14.4%) headache 11.3% (placebo 12.5%) back pain 4.8% (placebo 4.6%) NCT00363896 · Phase 3 · monotherapy show 34 more results200 μg once-daily headache 14.2% (placebo 12.7%) nasopharyngitis 12.7% (placebo 11.3%) upper respiratory tract infection 10.8% (placebo 9.8%) NCT00358436 · Phase 3 · monotherapy 400 μg upper respiratory tract infection 9.4% (placebo 8.9%) chronic obstructive pulmonary disease 7.9% (placebo 13%) NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 400/12 μg upper respiratory tract infection 11.8% (placebo 8.9%) chronic obstructive pulmonary disease 9.5% (placebo 13%) NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 400 μg copd exacerbation 13% (placebo 11.5%) upper respiratory tract infection 1.7% (placebo 0.5%) nasopharyngitis 1.1% (placebo 0%) NCT01045161 · Phase 3 400 μg copd exacerbation 27.9% (placebo 11.5%) upper respiratory tract infection 5.4% (placebo 0.5%) nasopharyngitis 4.1% (placebo 0%) NCT01045161 · Phase 3 200 μg copd exacerbation 8.7% (placebo 11.5%) upper respiratory tract infection 1.6% (placebo 0.5%) nasopharyngitis 1.1% (placebo 0%) NCT01045161 · Phase 3 200 μg to 400 μg copd exacerbation 22.7% (placebo 11.5%) nasopharyngitis 5.8% (placebo 0%) upper respiratory tract infection 5.8% (placebo 0.5%) NCT01045161 · Phase 3 400 μg Bid chronic obstructivce pulmonary disease 14.1% (placebo 20.5%) headache 12.3% (placebo 8.1%) nasopharyngitis 11.2% (placebo 8.4%) NCT01001494 · Phase 3 200 μg Bid chronic obstructivce pulmonary disease 15.9% (placebo 20.5%) nasopharyngitis 11.6% (placebo 8.4%) headache 10.8% (placebo 8.1%) NCT01001494 · Phase 3 urinary tract infection 5% (placebo 4.7%) upper respiratory tract infection 4.8% (placebo 5.6%) viral upper respiratory tract infection 4.4% (placebo 3.7%) NCT01966107 · Phase 4 400 μg headache 5.2% (placebo 9.7%) nasopharyngitis 3% (placebo 6.7%) NCT02375724 · Phase 4 · registry result, not featured evidence 400/12 μg chronic obstructive pulmonary 15.6% nasopharyngitis 11.5% headache 5.1% NCT02796677 · Phase 3 · registry result, not featured evidence 400/12 μg chronic obstructive pulmonary disease 20.3% (placebo 15.8%) urinary tract infection 8.2% (placebo 5.5%) nasopharyngitis 7.7% (placebo 4.8%) NCT01572792 · Phase 3 · registry result, not featured evidence 400/6 μg chronic obstructive pulmonary disease 22.1% (placebo 15.8%) nasopharyngitis 6.9% (placebo 4.8%) urinary tract infection 6.4% (placebo 5.5%) NCT01572792 · Phase 3 · registry result, not featured evidence 400/12 μg chronic obstructive pulmonary disease 15.2% (placebo 17.5%) cough 5.1% (placebo 3.6%) nasopharyngitis 4.8% (placebo 3.6%) NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3 400/6 μg chronic obstructive pulmonary disease 14.7% (placebo 17.5%) nasopharyngitis 5.1% (placebo 3.6%) cough 3.9% (placebo 3.6%) NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3 400/12 μg chronic obstructive pulmonary disease 8.6% (placebo 11.9%) nasopharyngitis 7.8% (placebo 7.2%) headache 7.5% (placebo 8.2%) NCT01462942 · Phase 3 · registry result, not featured evidence 400/6 μg chronic obstructive pulmonary disease 9.4% (placebo 11.9%) nasopharyngitis 7.9% (placebo 7.2%) headache 7.1% (placebo 8.2%) NCT01462942 · Phase 3 · registry result, not featured evidence 400 μg BID nasopharyngitis 6.3% (placebo 3.7%) NCT01471171 · Phase 3 · registry result, not featured evidence 400 µg BID nasopharyngitis 6.4% (placebo 2.4%) headache 3.5% (placebo 4.7%) NCT01462929 · Phase 3 · registry result, not featured evidence 400µg chronic obstructive pulmonary disease 19.9% NCT01044459 · Phase 3 · registry result, not featured evidence 200µg chronic obstructive pulmonary disease 19.3% NCT01044459 · Phase 3 · registry result, not featured evidence 400 μg chronic obstructive pulmonary disorder 22.6% nasopharyngitis 9.4% urinary tract infection 7.5% NCT00970268 · Phase 3 · registry result, not featured evidence 400 μg chronic obstructive pulmonary disorder 30.4% contusion 10.9% cough 8.7% NCT00970268 · Phase 3 · registry result, not featured evidence 200 μg chronic obstructive pulmonary disorder 24.7% nasopharyngitis 8.6% back pain 7.5% NCT00970268 · Phase 3 · registry result, not featured evidence 200 μg chronic obstructive pulmonary disorder 36.4% sinusitis 11.4% upper respiratory tract infection 11.4% NCT00970268 · Phase 3 · registry result, not featured evidence cough 5.8% (placebo 3.2%) headache 5.8% (placebo 7.4%) upper respiratory tract infection 5.8% (placebo 2.1%) NCT00500318 · Phase 3 · registry result, not featured evidence 400 μg Bid diarrhoea 6.9% (placebo 0%) chronic obstructive pulmonary disease 0% (placebo 10%) NCT00868231 · Phase 2 · registry result, not featured evidence | 62.5 mcgk upper respiratory tract infection 12.2% (placebo 12.9%) nasopharyngitis 9.3% (placebo 10.9%) dizziness 2.9% (placebo 2%) NCT02184611 · Phase 3 show 23 more results125 µg QD nasopharyngitis 5% (placebo 4.5%) headache 3% (placebo 4.5%) NCT01772147 · Phase 3 · combination 62.5 µg QD headache 4.4% (placebo 4.5%) nasopharyngitis 3% (placebo 4.5%) NCT01772147 · Phase 3 · combination 62.5 µg headache 4.4% (placebo 2.9%) back pain 3.4% (placebo 1.5%) nasopharyngitis 3.4% (placebo 3.4%) NCT01957163 · Phase 3 · combination 125 µg nasopharyngitis 4.8% (placebo 3.4%) headache 4.3% (placebo 2.9%) cough 3.4% (placebo 0.5%) NCT01957163 · Phase 3 · combination 125 µg nasopharyngitis 9.2% (placebo 10.7%) headache 1.9% (placebo 2.4%) back pain 1% (placebo 1.9%) NCT02119286 · Phase 3 · combination 62.5 µg nasopharyngitis 5.3% (placebo 10.7%) back pain 3.9% (placebo 1.9%) headache 3.9% (placebo 2.4%) NCT02119286 · Phase 3 · combination 125 µg QD headache 6.3% (placebo 4.9%) cough 2.4% (placebo 1.5%) nasopharyngitis 2.4% (placebo 4.9%) NCT01772134 · Phase 3 · combination 62.5 µg QD headache 4.4% (placebo 4.9%) cough 3.4% (placebo 1.5%) nasopharyngitis 2.5% (placebo 4.9%) NCT01772134 · Phase 3 · combination 62.5 mcg QD headache 8.1% nasopharyngitis 8.1% NCT02236611 · Phase 4 · registry result, not featured evidence 62.5 mcg+ICS/LABA nasopharyngitis 13.4% (placebo 14.5%) headache 3.4% (placebo 6.8%) cough 2.5% (placebo 4.3%) NCT02257372 · Phase 4 · registry result, not featured evidence · combination 100/62.5/25 viral upper respiratory tract infection 10.6% headache 6.1% upper respiratory tract infection 3.4% NCT02729051 · Phase 3 · registry result, not featured evidence 62.5 mcg QD headache 5.9% nasopharyngitis 5.3% NCT02207829 · Phase 3 · registry result, not featured evidence 62.5/25 µg headache 7.5% nasopharyngitis 6.6% cough 3.3% NCT02257385 · Phase 3 · registry result, not featured evidence 62.5/25mcg headache 6.5% (placebo 6.5%) nasopharyngitis 5.2% (placebo 6.5%) NCT02152605 · Phase 3 · registry result, not featured evidence 62.5/25 mcg headache 6.9% nasopharyngitis 4% NCT01879410 · Phase 3 · registry result, not featured evidence 62.5/25 µg once daily nasopharyngitis 4% headache 3.5% NCT01716520 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3 100/250 µg nasopharyngitis 1.9% toothache 0.5% dysphonia 0% NCT02164539 · Phase 2 · registry result, not featured evidence · combination 100/125 µg dysphonia 6.5% nasopharyngitis 4.3% toothache 0% NCT02164539 · Phase 2 · registry result, not featured evidence · combination 100/15.6 µg nasopharyngitis 7.1% toothache 7.1% dysphonia 0% NCT02164539 · Phase 2 · registry result, not featured evidence · combination 100/62.5 µg nasopharyngitis 5% dysphonia 2.5% toothache 2.5% NCT02164539 · Phase 2 · registry result, not featured evidence · combination 100/250/25 µg dysphonia 0% nasopharyngitis 0% toothache 0% NCT02164539 · Phase 2 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for both studies.
- bTreatment context has not been resolved for both arms.
- cAssessment timepoints differ: 24 weeks versus 8 weeks.
- dTrial phases differ: Phase 4 versus Phase 3.
- eAssessment timepoints differ: 12 weeks versus 3 weeks.
- fAssessment timepoints differ: 12 weeks versus 6 weeks.
- gThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- hAssessment timepoints differ: 24 weeks versus 52 weeks.
- iThe assessment timepoint is not available for both results.
- jPopulation comparability has not been reviewed for 31 of these studies.
- kPopulation comparability has not been reviewed for 25 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Aclidinium bromide
show 1 more result
show 3 more results
show 8 more results
show 8 more results
show 4 more results
show 5 more results
show 5 more results
show 3 more results
show 3 more results
show 1 more result
+ 22 further endpoints in the CSV export.
Umeclidinium
show 10 more results
show 2 more results
show 1 more result
show 3 more results
show 1 more result
show 1 more result
show 1 more result
+ 7 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Aclidinium bromide's landscape · Umeclidinium's landscape